^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Lung Adenocarcinoma

Related cancers:
16h
Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug-Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma. (PubMed, Biomedicines)
While tyrosine kinase inhibitors (TKIs) like gefitinib and osimertinib target this mutation, treatments often face challenges such as metastasis and resistance. It could support treatment strategy evaluations and potentially reduce trial sizes, promising more efficient and targeted therapeutic approaches. Following its consecutive prospective validations with the FLAURA2 and MARIPOSA trials (validation metrics computed from bootstrapped, weighted log-rank tests: 94.0% and 98.1%, respectively), the model could be used to generate a synthetic control arm.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib) • gefitinib
17h
Actin-Dependent Mechanism of Tumor Progression Induced by a Dysfunction of p53 Tumor Suppressor. (PubMed, Cancers (Basel))
These alterations in cell motility were closely associated with actin cytoskeleton restructuring, favoring γ-actin, and coincided with ERK1/2-mediated signaling activation, unveiling an innovative regulatory mechanism in malignancy progression. Cancer cell aggressiveness, driven by actin cytoskeleton reorganization and a shift towards γ-actin predominance, may be regulated by p53 dysfunction, thereby providing novel insight into tumor progression mechanisms.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation • TP53 wild-type • TP53 R175H • TP53 overexpression • TP53 R273H
18h
Monolayer culture alters EGFR inhibitor response through abrogation of microRNA-mediated feedback regulation. (PubMed, Sci Rep)
Results were confirmed in human lung adenocarcinoma tissue. HCC827 spheroids were resistant to erlotinib and gefitinib, but significantly more sensitive in 2D culture. Analysis of RNA-seq data suggests that cells in 2D culture become highly dependent on EGFR signaling to drive proliferation and cell spreading, resulting in a misleading level of sensitivity to EGFR TKIs, while the same cells in spheroid culture retain microRNA-driven EGFR feedback regulation that leaves them less vulnerable to EGFR inhibition. These findings underscore the need for close scrutiny of culture-induced effects on drug target regulation in model design for ex vivo drug screening.
Journal
|
MIR146A (MicroRNA 146a)
|
erlotinib • gefitinib
1d
Single-cell RNA sequencing integrated with bulk RNA sequencing analysis identifies a tumor immune microenvironment-related lncRNA signature in lung adenocarcinoma. (PubMed, BMC Biol)
This study developed a promising tool based on TIME-related lncRNAs, which might contribute to tailored treatment and prognosis management of LUAD patients.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression
1d
Sulforaphane inhibits the migration and invasion of BPDE-induced lung adenocarcinoma cells by regulating NLRP12. (PubMed, Toxicol Appl Pharmacol)
Lentivirus-mediated NLRP12 overexpression not only reversed the observed phenotype in BPDE-induced cells but also led to a reduction in the expression of critical factors associated with both canonical and non-canonical NF-κB pathways. Collectively, we found that SFN could inhibit BPDE-induced migration and invasion of A549 cells by upregulating NLRP12, thereby influencing both canonical and non-canonical NF-κB pathways.
Journal
|
CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • IL33 (Interleukin 33)
1d
Journal • Immune cell
|
CCL20 (C-C Motif Chemokine Ligand 20)
1d
Development and Validation of a Machine Learning Prognostic Model of m5C Related immune Genes in Lung Adenocarcinoma. (PubMed, Cancer Control)
The prognostic signature comprised of HLA-DMB, PPIA, and GPI based on m5C-IRGs was established, which might provide theoretical basis and reference value for the research of LUAD.
Journal • IO biomarker • Machine learning
|
HLA-DMB (Major Histocompatibility Complex, Class II, DM Beta) • PPIA (Peptidylprolyl Isomerase A)
1d
Silencing of circ_0088036 inhibits growth and invasion of lung adenocarcinoma through miR-203/SP1 axis. (PubMed, J Biochem Mol Toxicol)
In addition, lessening of miR-203 and enlarging of SP1 could eliminate the anticancer effect of short hairpin RNA-circ_0088036 on LUAD cells. Besides, the knockout of circ_0088036 hindered the growth of xenografted tumors in vivo. Circ_0088036 promoted the LUAD cell growth, invasion, and EMT via modulating the miR-203/SP1 axis in LUAD.
Journal
|
MIR203A (MicroRNA 203a) • SP1 (Sp1 Transcription Factor)
1d
Elucidating the anti-cancer potential of Cinnamomum tamala essential oil against non-small cell lung cancer: A multifaceted approach involving GC-MS profiling, network pharmacology, and molecular dynamics simulations. (PubMed, Heliyon)
CTEO triggered apoptosis by arresting the cell cycle, increasing ROS accumulation, causing mitochondrial depolarisation, and elevating caspase-3, caspase-8 and caspase-9 levels in A549 cells. The above study provides insights into the pharmacological mechanisms of action of Cinnamomum tamala essential oil against non-small cell lung cancer treatment, suggesting its potential as an adjuvant therapy.
Journal
|
IL6 (Interleukin 6) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • IL17A (Interleukin 17A) • MAPK3 (Mitogen-Activated Protein Kinase 3)
|
CASP3 elevation
1d
Clinical significance of postoperative folate receptor-positive circulating tumor cells (FR + CTCs) for long-term prognosis in patients with invasive adenocarcinoma (IAC) of the lung. (PubMed, Thorac Cancer)
The detection of FR + CTCs postoperatively was an independent predictor of recurrence in patients treated for stage I-III IAC. Standardized detection methods and optimal time points for assessment should be established in future studies.
Journal • Circulating tumor cells • Tumor cell
|
CA 19-9 (Cancer antigen 19-9)
2d
CHRYSALIS: Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=751, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2024 --> Jun 2025
Trial completion date • Metastases
|
ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • EGFR C797S • MET mutation • MET expression • EGFR exon 20 mutation • EGFR positive
|
carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
2d
G2 and S phase-expressed protein 1 is a biomarker for poor prognosis in lung adenocarcinoma. (PubMed, Medicine (Baltimore))
GTSE1 can be used as a marker and therapeutic target for LUAD. The survival of LUAD patients can be improved by reducing the expression of GTSE1.
Journal
|
GTSE1 (G2 And S-Phase Expressed 1)
2d
Treating anaplastic lymphoma kinase (ALK) fusion-driven metastatic non-small cell lung cancer (NSCLC) with alectinib through pregnancy. (PubMed, BMJ Case Rep)
For advanced lung adenocarcinomas, with no targetable driver mutations, there is evidence-based guidance on the use of carboplatin-paclitaxel chemotherapy after first trimester. In contrast, for epidermal growth factor receptor (EGFR)-mutated or anaplastic lymphoma kinase (ALK)-rearranged metastatic lung adenocarcinomas, there is a paucity of clinical data on the safety of EGFR and ALK tyrosine kinase inhibitors to mother and fetus for official guidelines to recommend the use of these otherwise-first-line therapies in pregnancy. Considering this knowledge gap, we present a case of a young gravida 1 para 0 (G1P0) woman who continued alectinib 300 mg oral two times per day for ALK-rearranged metastatic lung adenocarcinoma throughout all 36 weeks of her pregnancy and delivered a healthy baby at term via caesarean section (C-section).
Journal • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK rearrangement • ALK fusion
|
carboplatin • paclitaxel • Alecensa (alectinib)
2d
Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition. (PubMed, J Exp Clin Cancer Res)
Our research offers valuable insights into the use of AF for treating NSCLC and PDAC. It highlights AF's cancer cell selectivity, establishes CA12 as a predictive biomarker for AF sensitivity, and underscores the enhanced efficacy of AF when combined with MK2206 and other therapeutics. These findings pave the way for further exploration of AF in cancer treatment, particularly in identifying patient populations most likely to benefit from its use and in optimizing combination therapies for improved patient outcomes.
Journal
|
CA12 (Carbonic Anhydrase 12)
|
MK-2206
2d
GPX8+ cancer-associated fibroblast, as a cancer-promoting factor in lung adenocarcinoma, is related to the immunosuppressive microenvironment. (PubMed, BMC Med Genomics)
This study elucidates the association between GPX8+ CAFs and poor prognosis, as well as the induction of immunosuppressive formation in LUAD. These findings suggest that targeting GPX8+ CAFs could potentially serve as a therapeutic strategy for the treatment of LUAD.
Journal • IO biomarker
|
GPX8 (Glutathione Peroxidase 8)
3d
A Novel Gene Signature Based on Immune Cell Infiltration Landscape Predicts Prognosis in Lung Adenocarcinoma Patients. (PubMed, Curr Med Chem)
We used bioinformatics to determine a new, robust sixteen-gene signature. We also found that this signature's prognostic ability was closely related to the resting mast cell infiltration of LUAD patients.
Journal • Gene Signature • Immune cell
|
CD20 (Membrane Spanning 4-Domains A1) • EREG (Epiregulin) • CCR2 (C-C Motif Chemokine Receptor 2) • CYP4B1 (Cytochrome P450 Family 4 Subfamily B Member 1) • MS4A1 (Membrane Spanning 4-Domains A1) • TAP1 (Transporter 1) • HOXB9 (Homeobox B9) • S100P (S100 calcium binding protein P) • KLK12 (Kallikrein Related Peptidase 12)
3d
Combined detection of serum IL-6 and CEA contributes to the diagnosis of lung adenocarcinoma in situ. (PubMed, PeerJ)
IL-6 shows potential as a prospective serum biomarker for the diagnosis of AIS, and the combination of serum IL-6 with CEA may contribute to increased accuracy in AIS diagnosis. However, it is worth noting that further research is still necessary to validate and optimize the diagnostic efficacy of these biomarkers and to address potential sensitivity limitations.
Journal
|
IL6 (Interleukin 6) • CEACAM5 (CEA Cell Adhesion Molecule 5) • KRT19 (Keratin 19)
3d
The Dual Role of the NFATc2/galectin-9 Axis in Modulating Tumor-Initiating Cell Phenotypes and Immune Suppression in Lung Adenocarcinoma. (PubMed, Adv Sci (Weinh))
LGALS9, the gene encoding galectin-9, is found to be transcriptionally regulated by the nuclear factor of activated T cells 2 (NFATc2), a previously reported TIC regulator, via in silico prediction and luciferase reporter assays. Overall, the results suggest that the NFATc2/galectin-9 axis plays a dual role in TIC regulation and immune suppression.
Journal
|
NFATC1 (Nuclear Factor Of Activated T Cells 1) • LGALS9 (Galectin 9)
3d
The radiological characteristics, tertiary lymphoid structures, and survival status associated with EGFR mutation in patients with subsolid nodules like stage I-II LUAD. (PubMed, BMC Cancer)
In early-phase LUADs, subsolid nodules with EGFR mutation had specific clinical and radiological signatures. EGFR mutation was associated with worse survival outcomes and negatively correlated with TLS, which might weaken the positive impact of TLS on prognosis. Highly attention should be paid to the use of EGFR-TKI for further treatment as agents in early LUAD patients who carrying EGFR mutation.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR wild-type
3d
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
P2, N=6, Terminated, National Cancer Institute (NCI) | Trial completion date: Mar 2024 --> Dec 2023 | Active, not recruiting --> Terminated; Study was terminated due to slow accrual.
Trial completion date • Trial termination
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MSLN (Mesothelin) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
KRAS mutation • EGFR mutation • MSLN expression
|
Keytruda (pembrolizumab) • LMB-100
3d
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) (clinicaltrials.gov)
P2, N=5, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Feb 2025
Trial completion date
|
ALK (Anaplastic lymphoma kinase)
|
ALK rearrangement
|
Xalkori (crizotinib)
3d
Hexavalent chromium exposure activates the non-canonical nuclear factor kappa B pathway to promote immune checkpoint protein programmed death-ligand 1 expression and lung carcinogenesis. (PubMed, Cancer Lett)
The activation of the IL-6/Jak signaling axis by Cr(VI) exposure not only promoted inflammation but also stabilized the immune checkpoint molecule programmed death-ligand 1 (PD-L1) protein in the lungs, reducing T lymphocyte infiltration to the lungs. Given the well-recognized critical role of PD-L1 in inhibiting anti-tumor immunity, these findings suggested that the lncRNA ABHD11-AS1-mediated non-canonical NFκB pathway activation and PD-L1 up-regulation may play important roles in Cr(VI)-induced lung carcinogenesis.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
PD-L1 expression
3d
Prognostic value of KRAS G12V mutation in lung adenocarcinoma stratified by stages and radiological features. (PubMed, J Thorac Cardiovasc Surg)
KRAS G12V mutation was associated with aggressive clinical-pathological phenotype and early recurrence. To note, this mutation exhibited significantly worse prognosis in part-solid and stage Ⅰ lung adenocarcinoma patients. Meanwhile, the prognostic significance of KRAS G12C and G12V variants were comparable.
Journal • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • KDR (Kinase insert domain receptor) • FGF3 (Fibroblast growth factor 3)
|
PD-L1 expression • KRAS mutation • KRAS G12C • KRAS G12V • RET mutation • KRAS G12
3d
DNA variants detected in primary and metastatic lung adenocarcinoma: a case report and review of the literature. (PubMed, Lab Med)
We observed 7 DNA copy number aberrations (CNAs) in primary and metastatic tumor specimens; an additional 7 CNAs were exclusively detected in the metastatic tumor specimens. These DNA alterations may be genetic drivers in the pathogenesis of the tumor specimen from our patient and may serve as biomarkers for the classification and prognosis of NSCLC.
Review • Journal • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12D • KRAS G12 • KRAS exon 2 mutation
3d
Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments. (PubMed, Cancer Sci)
Immune checkpoint inhibitors could be an effective treatment for the PI subtype. Glycolysis is a potential target for converting an immunosuppressive TME into an antitumorigenic TME in the PP subtype.
Journal • IO biomarker
|
SLC2A1 (Solute Carrier Family 2 Member 1)
3d
Bioinformatics-based screening and analysis of the key genes involved in the influence of antiangiogenesis on myeloid-derived suppressor cells and their effects on the immune microenvironment. (PubMed, Med Oncol)
Antiangiogenic therapy may regulate MDSC infiltration through multiple important signaling pathways closely associated with tumor onset and development, such as cell differentiation, cell proliferation, the cell cycle, and immune responses. Antiangiogenic drugs may exert effects by affecting various types of infiltrating cells associated with immune suppression.
Journal
|
TOP2A (DNA topoisomerase 2-alpha) • AURKB (Aurora Kinase B) • CCNA2 (Cyclin A2) • NUSAP1 (Nucleolar and Spindle Associated Protein 1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • CENPA (Centromere protein A) • KIF2C (Kinesin Family Member 2C) • MGP (Matrix Gla Protein)
4d
Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung. (PubMed, Kaohsiung J Med Sci)
In summary, ramucirumab may have similar effectiveness as bevacizumab in combination with an EGFR-TKI as first line therapy for advanced lung adenocarcinoma harboring susceptible EGFR mutation. Further large-scale registry-based cohort studies may be needed to validate our findings.
Clinical data • Journal • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Avastin (bevacizumab) • Cyramza (ramucirumab)
4d
Exploring the Diagnostic and Prognostic Predictive Values of Ferroptosis- Related Markers in Lung Adenocarcinoma. (PubMed, Curr Pharm Biotechnol)
Therapeutic targeting of these genes using specific drugs holds great promise for revolutionizing drug discovery and improving the overall survival of LUAD patients.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
|
TP53 expression • KRAS expression
4d
Significance of ZO-1, an Intercellular Adhesion Molecule, as a Prognostic Marker in Lung Adenocarcinoma. (PubMed, Tokai J Exp Clin Med)
ZO-1-negative cases tended to have poorer prognoses in all histological types, with a poorer prognosis in the solid pattern. These results suggest that ZO-1 expression in solid-pattern lung adenocarcinoma may be a useful prognostic marker.
Journal
|
TJP1 (Tight Junction Protein 1)
4d
LungMate-007: Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer (clinicaltrials.gov)
P2, N=56, Active, not recruiting, Shanghai Pulmonary Hospital, Shanghai, China | Recruiting --> Active, not recruiting
Enrollment closed
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Ameile (aumolertinib)
4d
MRPS16 promotes lung adenocarcinoma growth via the PI3K/AKT/Frataxin signalling axis. (PubMed, J Cell Mol Med)
Moreover, MRPS16-knockdown-mediated Frataxin overexpression was shown to restore the reduction in tumour cells proliferation, migration and invasion. Our results revealed that MRPS16 caused an aggressive phenotype to LAUD and was a poor prognosticator; thus, targeting MRPS16 may be effectual in LAUD treatment.
Journal
|
RPS16 (Ribosomal Protein S16)
4d
microRNA-486-5p Regulates DNA Damage Inhibition and Cisplatin Resistance in Lung Adenocarcinoma by Targeting AURKB. (PubMed, Crit Rev Eukaryot Gene Expr)
The rescue experiment presented that high expression of microRNA-486-5p could weaken the impact of AURKB overexpression on LUAD cell behavior and DDP resistance. microRNA-486-5p regulated DNA damage to inhibit DDP resistance in LUAD by targeting AURKB, implying that microRNA-486-5p/AURKB axis may be a possible therapeutic target for DDP resistance in LUAD patients.
Journal
|
AURKB (Aurora Kinase B) • H2AX (H2A.X Variant Histone) • MIR486-1 (MicroRNA 486-1)
|
AURKB overexpression
|
cisplatin
5d
L-Methionine accentuates anti-tumor action of Gefitinib in Gefitinib-resistant lung adenocarcinoma: Role of EGFR/ERK/AKT signaling and histone H3K36me2 alteration. (PubMed, Toxicol Appl Pharmacol)
Notably, L-Methionine, functioning as a methyl group donor, elevated the expression of H3K36me2 (an activation mark), while reducing the p-ERK activity. Our study provides the first evidence supporting L-Methionine supplementation as a novel strategy to enhance Gefitinib chemosensitivity against pulmonary adenocarcinoma.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR H1975
|
gefitinib
5d
Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome. (PubMed, Drug Resist Updat)
In addition, proteomic analysis of brigatinib-treated cells revealed the upregulation of SRC kinase, a protein frequently activated in cancer...Our study demonstrates that the simultaneous inhibition of ALK and SRC can potentially overcome resistance mechanisms and enhance clinical outcomes in ALK-positive lung cancer patients. ONE SENTENCE SUMMARY: Co-targeting ALK and SRC enhances ALK inhibitor response in lung cancer by affecting the proteomic profile, offering hope for overcoming resistance and improving clinical outcomes.
Journal • Tumor cell
|
EML4 (EMAP Like 4)
|
ALK positive • EML4-ALK variant 3
|
Alunbrig (brigatinib)
6d
Exploratory pilot study to characterize the immune landscapes of malignant pleural effusions and their corresponding primary tumors from patients with breast carcinoma and lung adenocarcinoma. (PubMed, J Am Soc Cytopathol)
The immune cell phenotypes in the MPEs and PTs were similar within each cancer type but different between BC versus LADC. An MPE analysis can potentially be used as a substitute for a PT analysis, but an expanded study of this topic is essential.
Journal • Pleural effusion • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD68 (CD68 Molecule) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression
6d
NRF2 regulates EGF stability through OTUD4 in lung adenocarcinoma. (PubMed, Biochem Biophys Res Commun)
More importantly, OTUD4 and NRF2 expression was found being correlated in LUAD patients. The data collectively revealed a novel mechanism of NRF2 regulating on EGF stability through OTUD4 in LUAD.
Journal
|
NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • EGF (Epidermal growth factor)
|
EGF expression
6d
Modulation of autophagy affected tumorigenesis induced by the envelope glycoprotein of JSRV. (PubMed, Virology)
Last, mouse xenograft experiments indicated that inhibition of autophagy by 3-methyladenine suppressed both tumor growth and the epithelial-to-mesenchymal transition. In conclusion, JSRV, through JSRV Env, takes advantage of the autophagy process, leading to the development of OPA.
Journal
|
BECN1 (Beclin 1)
6d
NME6 as a potential biomarker and therapeutic target involved in immune infiltration for lung adenocarcinoma. (PubMed, Technol Health Care)
NME6 regulates genes related to m6A modification and immune cells infiltration. Furthermore, NME6 could sever as a potential therapeutic target for LUAD.
Journal
|
FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • YTHDC1 (YTH Domain Containing 1) • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1) • HNRNPC (Heterogeneous Nuclear Ribonucleoprotein C) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2) • METTL14 (Methyltransferase 14) • METTL3 (Methyltransferase Like 3) • WTAP (WT1 Associated Protein) • YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2) • RBM15 (RNA Binding Motif Protein 15) • VIRMA (Vir Like M6A Methyltransferase Associated) • YTHDF3 (YTH N6-Methyladenosine RNA Binding Protein F3) • ZC3H13 (Zinc Finger CCCH-Type Containing 13)
6d
A novel disulfidptosis-related prognostic gene signature and experimental validation identify ACTN4 as a novel therapeutic target in lung adenocarcinoma. (PubMed, Cancer Biomark)
Our study introduced a prognostic model based on DRGs, which could forecast the prognosis of patients with LUAD. The biomarker ACTN4 exhibits promise for the diagnosis and management of LUAD, given its correlation with tumor immune infiltration and m6A modification.
Journal • Gene Signature
|
ACTN4 (Actinin Alpha 4)
6d
Evaluation of the clinical significance of long non-coding RNA MALAT1 genetic variants in human lung adenocarcinoma. (PubMed, Aging (Albany NY))
Further analyses using the datasets from The Cancer Genome Atlas (TCGA) revealed that lower MALAT1 mRNA levels were associated with the advanced stage, and lymph node metastasis in LADC patients. In conclusion, our results showed that MALAT1 rs3200401 polymorphisms dramatically raised the probability of LUAD development.
Journal
|
EGFR (Epidermal growth factor receptor) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1)
|
EGFR mutation • EGFR wild-type
7d
Cios Mobile 3D Spin for Robotic Bronchoscopy (clinicaltrials.gov)
P=N/A, N=30, Active, not recruiting, Mayo Clinic | Trial completion date: Nov 2023 --> May 2024
Trial completion date
7d
A Study of PY314 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=86, Terminated, Ikena Oncology | Phase classification: P1a/1b --> P1 | N=288 --> 86 | Active, not recruiting --> Terminated; Sponsor business decision.
Phase classification • Enrollment change • Trial termination • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • TREM2 (Triggering Receptor Expressed On Myeloid Cells 2)
|
MSI-H/dMMR
|
Keytruda (pembrolizumab)